Adial Pharmaceuticals (ADIL) Net Income (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Net Income of -$2.0 million for Q1 2026, up 66.34% sequentially from -$5.8 million in Q3 2025, and up 16.14% YoY from -$1.7 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Net Income (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Net Income for 10 years, with the latest figure at -$2.0 million in Q1 2026.
- Quarterly Net Income rose 16.14% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.6 million (up 39.16% YoY) and the FY2025 annual result came in at -$24.4 million, down 84.86% from the prior year.
- Net Income improved to -$2.0 million in Q1 2026 per ADIL's latest filing, from -$5.8 million in the prior quarter.
- Over five years, Net Income peaked at -$15896.0 in Q4 2023 and troughed at -$11.1 million in Q3 2024.
- A 5-year average of -$2.7 million and a median of -$2.2 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2024: Net Income jumped 99.38% in 2023, then plunged 29749.4% in 2024.
- Over 5 years, Net Income stood at -$2.5 million in 2022, then surged by 99.38% to -$15896.0 in 2023, then slumped by 8979.62% to -$1.4 million in 2024, then tumbled by 302.35% to -$5.8 million in 2025, then surged by 66.34% to -$2.0 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$2.0 million, -$5.8 million, and -$2.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | -51.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.95 Mn |
| Sep 30, 2025 | -5.81 Mn |
| Jun 30, 2025 | -2.80 Mn |
| Mar 31, 2025 | -2.33 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Sep 30, 2024 | -11.13 Mn |
| Jun 30, 2024 | -2.46 Mn |
| Mar 31, 2024 | -6.48 Mn |
| Dec 31, 2023 | -15,896.00 |
| Sep 30, 2023 | -37,276.00 |
| Jun 30, 2023 | -64,226.00 |
| Mar 31, 2023 | -665,953.00 |
| Dec 31, 2022 | -2.55 Mn |
| Sep 30, 2022 | -1.99 Mn |
| Jun 30, 2022 | -610,652.00 |
| Mar 31, 2022 | -2.91 Mn |
| Dec 31, 2021 | -5.92 Mn |
| Sep 30, 2021 | -4.32 Mn |
| Jun 30, 2021 | -4.44 Mn |
| Mar 31, 2021 | -4.83 Mn |